Basit öğe kaydını göster

Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

dc.contributor.authorArtaç, Mehmet
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÇelik, S.
dc.contributor.authorÖzçelik, M.
dc.contributor.authorÖven, B.
dc.contributor.authorŞimşek, E.
dc.contributor.authorGeredeli, C.
dc.contributor.authorKaraca, M.
dc.contributor.authorCil, T.
dc.contributor.authorHarputluoğlu, Hakan
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorTürk, H. Mehmet
dc.contributor.authorKefeli, Umut
dc.contributor.authorAlacacıoğlu, Ahmet
dc.contributor.authorTural, D.
dc.contributor.authorSakin, A.
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorÇevik, Duygu
dc.contributor.authorDane, Faysal
dc.contributor.authorGümüş, Mahmut
dc.date.accessioned2022-08-12T07:33:50Z
dc.date.available2022-08-12T07:33:50Z
dc.date.issued2022en_US
dc.identifier.citationArtaç, M., Çubukçu, E., Bozkurt, O., Bilici, A., Çelik, S., Özçelik, M. ... Gümüş, M. (2022). Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study. Annals of Oncology içinde (S281-S282. ss.). https://doi.org/10.1016/j.annonc.2022.04.182en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.04.182
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9646
dc.description.abstractBackground: Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall survival (OS). Our aim was to study the real-life experience (onco-colon registry Turkey) of maintenance chemotherapy with antiEGFR or antiVEGF mAbs after the standart firstline doublet chemotherapy backbone in RAS wild-type mCRC patients.en_US
dc.description.sponsorshipAmgenen_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectMetastatic Colon Cancer (mCRC)en_US
dc.subjectChemotherapyen_US
dc.subjectOnco-Colon Turkey Studyen_US
dc.titleReal-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey studyen_US
dc.typeconferenceObjecten_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume33en_US
dc.identifier.issueSupplement:4en_US
dc.identifier.startpageS281en_US
dc.identifier.endpageS282en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.annonc.2022.04.182en_US
dc.institutionauthorBilici, Ahmet
dc.identifier.wosqualityQ1en_US
dc.identifier.wos000823826500105en_US


Bu öğenin dosyaları:

Thumbnail
Ad:
Bilici-Ahmet-2022.pdf
Boyut:
146.4Kb
Biçim:
PDF
Açıklama:
Tam Metin / Full Text
Göster/Aç

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster